Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIGHT: Biomarker-driven Therapy in Platinum-Resistant Ovarian Cancer
NCT05044871Phase 2Completed
- Sponsor
- Tongji Hospital
- Start
- Jul 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pamiparib, tislelizumab in ovarian cancer, sponsored by Tongji Hospital. Started Jul 2022; status: completed.
02
Drugs
pamiparibtislelizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05044871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044871.